Targeting the Warburg Effect with the Glucose Mutation Theory: A Case Study of 36-Year-Old Female Treated for Stage IV Metastatic TPBCUsing Glucosodiene Over a 15-Day Period

Abstract

Triple-positive breast cancer, characterized by the concurrent overexpression of estrogen receptors (ER+), progesterone receptors (PR+), and human epidermal growth factor receptor 2 (HER2+), presents a significant clinical challenge in oncology. This particular subtype, distinguished by its aggressive behavior and propensity for metastasis, necessitates a comprehensive therapeutic approach. Current treatment modalities, primarily centered around targeted therapies, encounter obstacles, underscoring the imperative to explore alternative interventions. The emergence of Glucosodiene, grounded in Maher Akl's hypothesis regarding glucose mutation, introduces a promising avenue for therapeutic intervention. This innovative pharmacological agent exhibits efficacy in targeting the Warburg effect, a characteristic feature of tumors reliant on anaerobic glucose metabolism. A positron emission tomography (PET) scan conducted on a 36-year-old female patient following oral administration of Glucosodiene at a daily dosage of 100 ml over 15 consecutive days revealed encouraging findings, including regression of lesions in the left breast and a favorable response in axillary lymph nodes. Additionally, improvement was evident in the abdomino-pelvic region and musculoskeletal system, indicative of a partial metabolic response compared to prior imaging studies. Noteworthy reductions were observed in the number, size, and metabolic activity of osseous lesions, indicative of favorable disease progression. The mechanistic underpinnings of Glucosodiene position it as a versatile and impactful therapeutic option in the landscape of cancer management, offering promise for enhanced patient outcomes. THE TRIAL IS REGISTERED UNDER CLINICALTRIALS.GOV NUMBER NCT05957939.